Fibrocell Science Inc., of Exton, Pa., published results in The Laryngoscope of a five-patient pilot study evaluating the safety and effectiveness of autologous fibroblasts to treat vocal fold scarring. The study showed that autologous fibroblasts cultured and expanded in Fibrocell's cGMP facility and injected into the lamina propria layer of the vocal folds as an outpatient procedure appeared to be well tolerated and produced both objective and subjective improvements in voice quality that were sustained up to 12 months after treatment.